News

Dr Reddy's Laboratories shares in focus after Q1; should you buy, sell or hold?
The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.
Dr. Reddy’s US generics business drags Q1 earnings, eyes weight-loss drug launch in 87 countries
The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...